PE20010568A1 - Formulaciones orales de liberacion controlada - Google Patents

Formulaciones orales de liberacion controlada

Info

Publication number
PE20010568A1
PE20010568A1 PE2000001020A PE0010202000A PE20010568A1 PE 20010568 A1 PE20010568 A1 PE 20010568A1 PE 2000001020 A PE2000001020 A PE 2000001020A PE 0010202000 A PE0010202000 A PE 0010202000A PE 20010568 A1 PE20010568 A1 PE 20010568A1
Authority
PE
Peru
Prior art keywords
active agent
microns
controlled release
water
release formulations
Prior art date
Application number
PE2000001020A
Other languages
English (en)
Inventor
Rajen Shah
Oskar Kalb
Satish Chandra Khanna
Jorg Ogorka
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20010568(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20010568A1 publication Critical patent/PE20010568A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN NUCLEO QUE CONTIENE UN AGENTE FARMACOLOGICAMENTE ACTIVO, TAL COMO RIVASTIGMINA, EL CUAL LIBERA UNA DOSIS EFECTIVA DE AGENTE ACTIVO DESPUES DE 6 h A 12 h DE SU INGESTION; Y, B) UN RECUBRIMIENTO QUE TIENE UN ESPESOR DE 50 MICRAS A 800 MICRAS, QUE COMPRENDE UNA PELICULA EXTERNA PERMEABLE AL AGUA O A LOS FLUIDOS CORPORALES, Y UNA PELICULA INTERNA EN FORMA DE UNA MEMBRANA QUE ES SEMIPERMEABLE AL AGUA O A LOS FLUIDOS CORPORALES. DONDE, LA LIBERACION DEL AGENTE ACTIVO FARMACEUTICO O UNA MEZCLA DE AGENTES ACTIVOS, SE DA DE UNA MANERA SUSTANCIALMENTE INDEPENDIENTE DE LA CONCENTRACION Y TIPO DE IONES PRESENTES EN EL MEDIO AMBIENTE GASTROINTESTINAL, COMO IONES DE H, OH, ES DECIR INDEPENDIENTEMENTE DEL pH Y DE LAS ENZIMAS PRESENTES EN EL FLUIDO CORPORAL. DICHA COMPOSICION SE UTILIZA PARA EL TRATAMIENTO DE PACIENTES CON DEMENCIA LIGERA A MODERADAMENTE SEVERA DEL TIPO ALZHEIMER
PE2000001020A 1999-09-29 2000-09-27 Formulaciones orales de liberacion controlada PE20010568A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9923045.0A GB9923045D0 (en) 1999-09-29 1999-09-29 New oral formulations

Publications (1)

Publication Number Publication Date
PE20010568A1 true PE20010568A1 (es) 2001-05-29

Family

ID=10861819

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001020A PE20010568A1 (es) 1999-09-29 2000-09-27 Formulaciones orales de liberacion controlada

Country Status (31)

Country Link
US (2) US20060246101A1 (es)
EP (1) EP1216032B1 (es)
JP (1) JP2003510268A (es)
KR (2) KR100661441B1 (es)
CN (1) CN1213737C (es)
AR (1) AR025792A1 (es)
AT (1) ATE384517T1 (es)
AU (1) AU769646B2 (es)
BR (1) BR0014440A (es)
CA (1) CA2379595A1 (es)
CO (1) CO5210867A1 (es)
CY (1) CY1107923T1 (es)
CZ (1) CZ301455B6 (es)
DE (1) DE60037897T2 (es)
DK (1) DK1216032T3 (es)
EC (1) ECSP003685A (es)
ES (1) ES2299438T3 (es)
GB (1) GB9923045D0 (es)
HU (1) HUP0202744A3 (es)
IL (2) IL148908A0 (es)
MY (1) MY128759A (es)
NO (1) NO331480B1 (es)
NZ (1) NZ517335A (es)
PE (1) PE20010568A1 (es)
PL (1) PL200822B1 (es)
PT (1) PT1216032E (es)
RU (1) RU2281758C2 (es)
SK (1) SK286651B6 (es)
TR (1) TR200200683T2 (es)
WO (1) WO2001022944A1 (es)
ZA (1) ZA200202369B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
SG164375A1 (en) 2004-08-13 2010-09-29 Boehringer Ingelheim Int Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EP2135602A1 (en) 2004-08-13 2009-12-23 Boehringer Ingelheim International GmbH Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
JP2008525313A (ja) * 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬の安定化方法
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
CN101797236B (zh) * 2010-03-23 2012-05-23 西南大学 重酒石酸卡巴拉汀口腔崩解片及其制备方法
CA2821504C (en) 2010-09-20 2019-03-26 Spi Pharma, Inc. Microencapsulation process and product
KR101990951B1 (ko) 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
CN106000294B (zh) * 2016-07-04 2019-04-30 三峡大学 一种高膨胀低收缩率膨润土及制备方法
CN115192538B (zh) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 一种压制包衣型硝苯地平缓释片及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US4984807A (en) * 1990-01-12 1991-01-15 Baruch Shiryon Board game
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
ES2067957T3 (es) * 1990-08-07 1995-04-01 Pfizer Uso de membranas polimerizadas interfacialmente en dispositivos de liberacion.
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
JP3950175B2 (ja) * 1997-05-30 2007-07-25 オスモティカ・コーポレイション 多層浸透デバイス
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR100412327B1 (ko) * 1997-07-01 2003-12-31 화이자 인코포레이티드 서트랄린 염 및 서트랄린의 서방성 투여형
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
ATE286725T1 (de) * 1998-10-01 2005-01-15 Novartis Pharma Gmbh Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system

Also Published As

Publication number Publication date
GB9923045D0 (en) 1999-12-01
CN1213737C (zh) 2005-08-10
DE60037897T2 (de) 2008-12-24
IL148908A (en) 2010-06-16
CZ20021028A3 (cs) 2002-06-12
CY1107923T1 (el) 2013-09-04
KR100661441B1 (ko) 2006-12-27
EP1216032A1 (en) 2002-06-26
PT1216032E (pt) 2008-04-29
AU1019701A (en) 2001-04-30
KR20050100710A (ko) 2005-10-19
DE60037897D1 (de) 2008-03-13
NO331480B1 (no) 2012-01-16
NZ517335A (en) 2003-10-31
SK286651B6 (sk) 2009-03-05
ZA200202369B (en) 2002-12-24
PL354075A1 (en) 2003-12-15
DK1216032T3 (da) 2008-06-02
CA2379595A1 (en) 2001-04-05
ES2299438T3 (es) 2008-06-01
CO5210867A1 (es) 2002-10-30
HUP0202744A2 (hu) 2003-01-28
NO20021452D0 (no) 2002-03-22
US20060246101A1 (en) 2006-11-02
ATE384517T1 (de) 2008-02-15
RU2281758C2 (ru) 2006-08-20
TR200200683T2 (tr) 2002-07-22
WO2001022944A1 (en) 2001-04-05
CN1376058A (zh) 2002-10-23
KR20020038778A (ko) 2002-05-23
SK4132002A3 (en) 2002-10-08
JP2003510268A (ja) 2003-03-18
IL148908A0 (en) 2002-09-12
US20110038897A1 (en) 2011-02-17
EP1216032B1 (en) 2008-01-23
WO2001022944A8 (en) 2001-07-26
AR025792A1 (es) 2002-12-11
HUP0202744A3 (en) 2004-05-28
ECSP003685A (es) 2002-05-23
CZ301455B6 (cs) 2010-03-10
MY128759A (en) 2007-02-28
NO20021452L (no) 2002-03-22
AU769646B2 (en) 2004-01-29
BR0014440A (pt) 2002-06-18
PL200822B1 (pl) 2009-02-27

Similar Documents

Publication Publication Date Title
PA8509001A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
PE88699A1 (es) Formas de dosificacion de liberacion sostenida de sertralina
ES2561108T3 (es) Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo
PE20001286A1 (es) FORMULACIONES FARMACEUTICAS DE LIBERACION CONTROLADA DE INHIBIDORES DE GMPc PDE-5
PE20010568A1 (es) Formulaciones orales de liberacion controlada
ECSP077182A (es) Metodos para el tratamiento de infecciones endobronquiales
SE8703034L (sv) Oralt terapeutiskt system med systemisk verkan
YU54499A (sh) Farmaceutski preparat za primenu na mukozu
AR006652A1 (es) Forma farmacéutica de dosificación oral para el tratamiento oral de enfermedades óseas.
PE20001058A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
AR052855A1 (es) Composiciones para el cuidado bucal que contienen un extrato de eucalyptus
AR038947A1 (es) Suspension oral de sabor agradable y metodo
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
HUP0202749A2 (hu) Levoszimendánt tartalmazó oldat formájú gyógyszerkészítmény
PE20030287A1 (es) Composiciones farmaceuticas de terbinafina
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
BRPI0606119B8 (pt) preparações injetáveis de diclofenaco e seus sais farmaceuticamente aceitáveis
BG106602A (en) Formulation of substituted benzimidazoles
AR037356A1 (es) Forma de dosificacion oral de una prodroga de sulfonamida
UY27644A1 (es) Sistema de suministro osmótico
AR043536A1 (es) Composicion farmaceutica que comprende acido 5-metil-2-(2´-cloro-6´-fluoroanilino)fenilacetico
UY27373A1 (es) Formulaciones de interferón beta-humano
CO6160302A2 (es) Formulaciones farmaceuticas
ATE462419T1 (de) Orale pharmazeutische zusammensetzung für weichkapseln mit vinorelbin und behandlungsverfahren
GT199900171A (es) Concentrado oral de sertralina.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed